Osstell announces appointment of new CEO
Gothenburg, Sweden, August 19th: Osstell, the company that developed the original ISQ diagnostic technology, today announced that Malin Gustavsson has been appointed Chief Executive Officer (CEO) and will assume the position end of September.
Gothenburg, Sweden, August 19th:
Osstell, the company that developed the original ISQ diagnostic technology, today announced that Malin Gustavsson has been appointed Chief Executive Officer (CEO) and will assume the position end of September.
Malin Gustavsson will succeed Jonas Ehinger, who will take on a new challenge. Gustavsson has more than 15 years of senior management experience in the medical device industry, including Straumann and the past 9 years at Elos Medtech, a leading global development and manufacturing company for medical devices, as Global Communication & Marketing Director.
“I am very happy to have been entrusted to lead and contribute to the company’s continued growth together with the board and the team at Osstell. Since I worked in the dental industry for many years, I know the company from before and its strong brand. I am very much looking forward to taking over as CEO at Osstell shortly and to getting to know both the customers, partners and the employees more closely, along with its business, to drive the company’s strategy with a strong focus on delivering clinical value to the market.”, said Malin Gustavsson.
Jonas Ehinger and Malin Gustavsson
Klaus Maier, W&H Group CEO, commented “Malin’s extensive experience within the dental market, her business development and managerial skills will help drive further growth of Osstell and will be of great value to the W&H Group. We are excited to welcome Malin”. Mr Maier added “We are sad to see Jonas leave Osstell and the W&H Group but are very grateful for his contributions and dedicated continuous development and now wish him the very best in his new assignment.”
Ehinger will take on a new CEO assignment outside the dental and medical industry. Jonas Ehinger has led Osstell through a strong growth phase and different owner structures during the past twelve years, developing and executing the strategy focusing on Osstell’s proprietary ISQ technology, and now OsstellConnect as a strategy for the coming years. Osstell’s clinical relevance and value for clinicians and patients will remain the focus of the company moving forward.
Osstell (www.osstell.com) is the global leader in implant stability measurement and osseointegration monitoring. Osstell was formed in 1999 to commercialize an invention using Resonance Frequency Analysis (RFA) to determine the clinical status of a dental implant. Osstell’s proprietary and patented technology helps dentists around the world make dental implant treatments predictable, by measuring the stability of implants objectively and using the Osstell ISQ scale (Implant Stability Quotient). More than 1300 scientific publications confirm the benefits of the technology, its clinical value, and the use of the Osstell ISQ scale for dentists in their daily practice. Osstell is headquartered in Gothenburg, Sweden – the birthplace of dental implants. Since February 2018, Osstell is owned by W&H Group (www.wh.com).